Table 2.
Fracture risk in postmenopausal women without a prevalent vertebral fracture*
| Fracture type | Placebo (%) | Alendronate (%) | Fracture risk (95% CI) |
|---|---|---|---|
| Morphometric ≥1 | 78 (3.8) | 43 (2.1) | 0.56 (0.39–0.80) |
| Morphometric ≥2 | 10 (0.5) | 4 (0.2) | 0.40 (0.13–1.24) |
| Clinical vertebral** | |||
| Any clinical | 312 (14.1) | 272 (12.3) | 0.86 (0.73–1.01) |
| Any non-vertebral | 294 (13.3) | 261 (11.8) | 0.88 (0.74–1.04) |
| Hip | 24 (1.1) | 19 (0.9) | 0.79 (0.43–1.44) |
| Wrist | 70 (3.2) | 83 (3.7) | 1.19 (0.87–1.64) |
| Height loss (mm) | 8.5 | 7.0 | p<0.001 |
*
Note: Cummings et al 1998
**
Clinical vertebral fractures included in “any clinical” fractures.
Abbreviations: CI, confidence interval.